Horna, Pedro http://orcid.org/0000-0003-4909-6157
Weybright, Matthew J. http://orcid.org/0009-0007-5658-936X
Ferrari, Mathieu http://orcid.org/0000-0001-8535-7348
Jungherz, Dennis
Peng, YaYi
Akbar, Zulaikha
Tudor Ilca, F.
Otteson, Gregory E.
Seheult, Jansen N.
Ortmann, Janosch http://orcid.org/0000-0002-3811-6047
Shi, Min http://orcid.org/0000-0002-5741-4293
Maciocia, Paul M. http://orcid.org/0000-0002-9757-8073
Herling, Marco
Pule, Martin A.
Olteanu, Horatiu http://orcid.org/0000-0001-5783-4485
Article History
Received: 1 December 2023
Revised: 7 February 2024
Accepted: 9 February 2024
First Online: 29 February 2024
Conflict of interest
: MP and PMM are inventors on a patent describing the use of TRBC1/2 for diagnosis and treatment of T-cell malignancies. MP and MF are inventors on a patent describing TRBC2 antibodies. Autolus Therapeutics owns patents claiming the use of TRBC1/2 for diagnosis. MP, MF, and ZA own stock in and are employees of Autolus Therapeutics. FTI is a former Autolus employee. The remaining authors declare no competing interests.